The alarming rate of obesity and weight gain in industrialized nations is one of the most concerning health issues plaguing developed countries today. Scientists might have just come much closer to finally ending this epidemic by preventing mice from gaining weight even with a steady diet of high-fat food. Could these findings lead to effortless weight loss?
Published on eLife, the study described how scientists from Washington University School of Medicine basically activated certain pathways in fat cells, which essentially allowed the mice to go on a high-fat diet without becoming obese. This could lead to some huge leaps in treating all the other diseases that are associated with weight gain, including type-2 diabetes.
“Here by inducing expression of constitutively active Smoothened (SmoM2) or Gli2 (ΔNGli2) in the adipocyte lineage of postnatal mice, we show that targeted activation of Hh signaling suppresses high-fat-diet-induced obesity and improves whole-body glucose tolerance and insulin sensitivity,” the study reads.
As senior investigator Fanxin Long, Ph.D. put it, these findings could lead to new ways to treat the growing obesity epidemic afflicting populations even in developing countries. It also makes preventing weight gain easier because it targets the root cause of the issue.
"This could lead us to a new therapeutic target for treating obesity," Long said. "What's particularly important is that the animals in our study ate a high-fat diet but didn't gain weight, and in people, too much fat in the diet is a common cause of obesity."
On that note, translating the results of this study to apply to humans might not be that easy, MedicalXpress reports. The test subjects and people don’t exactly have the same metabolism and the methods used to activate the pathways in fat cells to stop them from growing might cause unknown side-effects. It might even cause cancer if the application is not done properly.


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



